| HOME >> BIOLOGY >> TECHNOLOGY |
SINGAPORE, March 6 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. Dr. Stephen Rhind, Senior Vice President Corporate Development, S*BIO, received the award on behalf of the company, from Mr. S. Iswaran, Singapore's Senior Minister for Trade and Industry.
The Annual BioSpectrum awards recognize outstanding contributions to the growth of the biotechnology and life sciences industry in Asia. S*BIO was chosen for its innovative business model and leading position in Singapore's biotechnology industry.
"We are proud to be named Singapore's emerging bioscience company of the year," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Receiving this award not only reflects S*BIO's leading role in oncology drug discovery and development but also demonstrates the commitment of Singapore's government to the local biomedical sciences industry.
"We thank everyone at S*BIO whose combined efforts led to the significant progress we made in moving our leading candidates, the JAK2 inhibitors SB1518 and SB1578, the HDAC inhibitor SB939, and the multi-kinase inhibitor SB1317, through pre-clinical and clinical development."
About BioSpectrum
Launched in 2003 by Asia's leading specialty publishing company, CyberMedia India Ltd., BioSpectrum is India's and Asia-Pacific's most widely circulated and read Life Sciences media platform. It comes out in two monthly editions: India edition published from Banglaore and an Asian edition, printed and published from Singapore. The business-to-business magazine tracks the growth of life science companies, captures the emerging technological and entrepreneurial trends in the area of Life Sciences which include pharmaceutical, biotechnology, medical technology, bio-agriculture and bio-fuels. The combined readership of both the editions of the magazine, which is available in m
'/>"/>
| SOURCE S*BIO Pte Ltd Copyright©2009 PR Newswire. All rights reserved |